


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Me,Et,n-Pr,n-Bu,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:25:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 80 TO 560

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 16:25:13 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 345 TO ITERATE

100.0% PROCESSED 345 ITERATIONS

51 ANSWERS

SEARCH TIME: 00.00.02

L3 51 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.88

186.10

FILE 'CAPLUS' ENTERED AT 16:25:18 ON 07 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 May 2009 VOL 150 ISS 19
FILE LAST UPDATED: 6 May 2009 (20090506/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

=> s 13


L4 4 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:193627 CAPLUS
 DOCUMENT NUMBER: 146:274087
 TITLE: Preparation of α -thioesters and benzenesulfonates as their intermediates
 INVENTOR(S): Fujiwara, Yuji; Takahashi, Kazuhiko
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan; Dainippon Pharmaceutical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 20pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007045793	A	20070222	JP 2005-234320	20050812
PRIORITY APPLN. INFO.:			JP 2005-234320	20050812

OTHER SOURCE(S): MARPAT 146:274087
 GI



AB (optically active) α -thioesters I [R1 = H, halo, alkoxy; R2 = alkyl; R4 = H, alkyl(oxy), aryl(oxy), alkoxy-carbonyl, cyano], useful as intermediates for benzothiazine-3-ones as matrix metalloprotease inhibitors, are prepared by treatment of (optically active) benzenesulfonates II [R1, R2 = same as above; R3 = H, alkyl(oxy), aryl(oxy), halo, NO2, cyano, alkoxy-carbonyl] with 2-nitrothiophenols (R4 = same as above) under basic conditions. Thus, Me (R)-2-hydroxy-5-(4-methoxyphenyl)pentanoate (97.5% ee) was tosylated and treated with Et 4-mercapto-3-nitrobenzoate and N-methylmorpholine to give the corresponding α -thioester (97.0% ee) with 69.1% yield.
 IT 864162-60-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of α -thioesters as intermediates for benzothiazinones as matrix metalloprotease inhibitors via benzenesulfonates)
 RN 864162-60-7 CAPLUS


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:979628 CAPLUS
 DOCUMENT NUMBER: 143:286436
 TITLE: Preparation of 1,4-benzothiazine-3-one derivatives as MMP-13 inhibitors
 INVENTOR(S): Samizo, Fumio; Horiuchi, Yoshihiro; Fukuda, Nobuhisa; Tsuboi, Katsumori; Makita, Atsushi
 PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082872	A1	20050909	WO 2005-JP3821	20050228
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2560664	A1	20050909	CA 2005-2560664	20050228
EP 1726587	A1	20061129	EP 2005-720093	20050228
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20080058321	A1	20080306	US 2007-598516	20070618
PRIORITY APPLN. INFO.:			JP 2004-57808	A 20040302
			WO 2005-JP3821	W 20050228


OTHER SOURCE(S): MARPAT 143:286436
 GI

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-, ethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB Title compds. represented by the formula I [wherein R = H or Et; R1 = halo(alkyl), (halo)alkoxy; n = 3 or 4; and pharmaceutically acceptable salts thereof] were prepared as matrix metalloprotease 13 (MMP-13) inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of anisole with succinic acid anhydride. II showed inhibition of MMP-13 with an IC50 value of 440 nM and cartilage degeneration with 52% inhibition rate at 50 mg/Kg. Thus, I and their pharmaceutical compds. are useful as MMP inhibitors for the treatment or prevention of cartilage degeneration and inflammations.
 IT 864162-54-9P 864162-60-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 1,4-benzothiazine-3-one derivs. as MMP-13 inhibitors)
 RN 864162-54-9 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 864162-60-7 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,


3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-, ethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




IT 864162-55-0P 864162-56-1P 864162-57-2P
 864162-58-3P 864162-59-4P 864162-61-8P
 864162-62-9P 864162-63-0P 864162-64-1P
 864162-65-2P 864162-66-3P 864162-67-4P
 864162-76-5P 864162-91-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,4-benzothiazine-3-one derivs. as MMP-13 inhibitors)
 RN 864162-55-0 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 2-[3-(4-chlorophenyl)propyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 864162-56-1 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 2-[3-(4-fluorophenyl)propyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864162-61-8 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo- (CA INDEX NAME)




RN 864162-62-9 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 2-[3-(4-chlorophenyl)propyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)




RN 864162-63-0 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 2-[3-(4-fluorophenyl)propyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864162-57-2 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[3-(4-(trifluoromethoxy)phenyl)propyl]-, ethyl ester (CA INDEX NAME)




RN 864162-58-3 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[3-(4-(trifluoromethyl)phenyl)propyl]-, ethyl ester (CA INDEX NAME)




RN 864162-59-4 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-(4-methoxyphenyl)butyl]-3-oxo-, ethyl ester (CA INDEX NAME)


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864162-64-1 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[3-(4-(trifluoromethoxy)phenyl)propyl]- (CA INDEX NAME)




RN 864162-65-2 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[3-(4-(trifluoromethyl)phenyl)propyl]- (CA INDEX NAME)



RN 864162-66-3 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-(4-methoxyphenyl)butyl]-3-oxo- (CA INDEX NAME)


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864162-67-4 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,

3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 864162-76-5 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,

3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-, ethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 864162-91-4 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,


3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:532639 CAPLUS
DOCUMENT NUMBER: 139:100932
TITLE: Preparation of hydroxamic acid derivatives as MMP inhibitors
INVENTOR(S): Horiuchi, Yoshihiro
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Japan
SOURCE: PCT Int., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055851	A1	20030710	WO 2002-JP13580	20021226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2471814	A1	20030710	CA 2002-2471814	20021226
AU 2002361096	A1	20030715	AU 2002-361096	20021226
EP 1466899	A1	20041013	EP 2002-792000	20021226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, ES, US 20050282905				
US 7504537	E2	20090317	US 2004-500218	20040625
PRIORITY APPLN. INFO.:			JP 2001-397638	A 20011227
			WO 2002-JP13580	W 20021226

OTHER SOURCE(S): MARPAT 139:100932
GI




AB The title compds. I [R1 and R2 each represents hydrogen, lower alkyl, lower haloalkyl, etc.; X represents methylene or NR3 (R3 represents hydrogen, lower alkyl, etc.); and R4 represents C1-4 alkyl] are prepared. Compds. of this invention in vitro showed IC50 values of < 0.5 nM to 34.4 nM against MMP-13. Formulations are given.

IT 302836-11-9P 302836-18-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


3-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry. Rotation (+).




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

(Uses)
(prepn. of hydroxamic acid derivs. as MMP inhibitors)
RN 302836-11-9 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-3-oxo-, ethyl ester (CA INDEX NAME)



RN 302836-18-6 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-3-oxo- (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:756696 CAPLUS
 DOCUMENT NUMBER: 133:321892
 TITLE: Preparation of hydroxamic acid derivatives as matrix metallo-proteinase inhibitors
 INVENTOR(S): Scarlato, Gerard Robert; Hadida Ruah, Sara Sabina; Nishimura, Tamiki; Nakatsuka, Masashi; Samizo, Fumio; Kamikawa, Yumiko; Houtigai, Hitoshi
 PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 218 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063197	A1	20001026	WO 2000-US10383	20000419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,				
ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2369947	A1	20001026	CA 2000-2369947	20000419
CA 2369947	C	20080617		
EP 1173427	A1	20020123	EP 2000-922291	20000419
EP 1173427	B1	20060405		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2002542238	T	20021210	JP 2000-612289	20000419
AT 322487	T	20060415	AT 2000-922291	20000419
ES 2261196	T3	20061116	ES 2000-922291	20000419
US 6713477	B1	20040330	US 2001-959192	20011109
PRIORITY APPLN. INFO.:			US 1999-129933P	P 19990419
			WO 2000-US10383	W 20000419

OTHER SOURCE(S): MARPAT 133:321892
 GI

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




AB The title compds. [I; X = (un)substituted alkylene, ortho-heteroarylene; Y1 = O, S, SO, SO2; Y2 = O, S; one of R1 and R3 = (CHR4)NCR5R6CONHOH; the other R1 and R3 = H, (un)substituted alkyl, cycloalkyl; R2 = H, (un)substituted alkyl, alkenyl, etc.; R4-R6 = H, (un)substituted alkyl, alkenyl, etc.; or R5 may be joined with R4 or R6 to form, with the carbon atom which they attach (un)substituted cycloalkane or heterocycloalkane;


n = 0-4], useful as matrix metallo-proteinase (e.g., MMP-2, MMP-3, MMP-9, and MMP-13) inhibitors, were prepared. E.g., a multi-step synthesis of 1,4-benzothiazine-3(4H)-one II which showed IC50 of 1.0 μ M against MMP-2, and 20% inhibition of TNF- α production at 5 μ M, was given.

IT 302834-55-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of hydroxamic acid derivs. as matrix metallo-proteinase inhibitors)
 RN 302834-55-5 CAPLUS
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-methoxyphenyl)methyl]-3-oxo-, methyl ester (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




IT 302833-93-8P 302833-98-3P 302834-00-0P
 302834-01-1P 302834-02-2P 302834-03-3P
 302834-06-6P 302834-12-4P 302834-13-5P
 302834-14-6P 302834-15-7P 302834-16-8P
 302834-17-9P 302834-54-4P 302834-56-6P
 302834-57-7P 302834-58-8P 302835-46-7P
 302836-03-9P 302836-05-1P 302836-08-4P
 302836-09-5P 302836-10-8P 302836-11-9P
 302836-12-0P 302836-13-1P 302836-14-2P
 302836-15-3P 302836-16-4P 302836-17-5P
 302836-18-6P 302836-19-7P 302836-20-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of hydroxamic acid derivs. as matrix metallo-proteinase inhibitors)
 RN 302833-93-8 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-methoxyphenyl)methyl]-3-oxo- (CA INDEX NAME)




RN 302833-98-3 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)- (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 302834-00-0 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 2-[(4-(4-chlorophenoxy)phenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)




RN 302834-01-1 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 302834-02-2 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 2-[(4-(4-chlorophenoxy)phenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 302834-03-3 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 302834-06-6 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-,
 sodium salt (1:1) (CA INDEX NAME)




● Na

RN 302834-12-4 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-methoxyphenyl)methyl]-3-oxo-, ethyl ester (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 302834-16-8 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[[4-(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 302834-17-9 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 2-[(4-fluorophenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)




RN 302834-54-4 CAPLUS
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-methoxyphenyl)methyl]-3-oxo- (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 302834-13-5 CAPLUS
 CN 2H-1,4-Benzothiazine-8-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-,
 ethyl ester (CA INDEX NAME)




RN 302834-14-6 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-,
 ethyl ester (CA INDEX NAME)




RN 302834-15-7 CAPLUS
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 302834-56-6 CAPLUS
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[(4-methoxyphenyl)methyl]-3-oxo-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 302834-57-7 CAPLUS
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,
 2-[(4-chlorophenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)




RN 302834-58-8 CAPLUS
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[(4-phenoxypheyl)methyl]- (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 302835-46-7 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)- (CA INDEX NAME)




RN 302836-03-9 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-hydroxyphenyl)methyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 302836-05-1 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[[4-(trifluoromethoxy)phenyl]methyl]-, ethyl ester (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 302836-11-9 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[[4-[(methylsulfonyl)phenoxy]phenyl]methyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 302836-12-0 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[[4-(4-pyridinyloxy)phenyl]methyl]- (CA INDEX NAME)




RN 302836-13-1 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[[4-(1,3-benzodioxol-5-yloxy)phenyl]methyl]-3-oxo-, ethyl ester (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 302836-08-4 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
2-[[4-(1,3-benzodioxol-5-yloxy)phenyl]methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 302836-09-5 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
2-[[4-(3-fluorophenoxy)phenyl]methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 302836-10-8 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[[4-(3-methoxyphenoxy)phenyl]methyl]-3-oxo-, ethyl ester (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 302836-14-2 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[[4-(3-(trifluoromethyl)phenoxy)phenyl]methyl]- (CA INDEX NAME)



RN 302836-15-3 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
2-[[4-(3-fluorophenoxy)phenyl]methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)




RN 302836-16-4 CAPLUS
CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[[4-(4-methoxyphenyl)sulfonyl]phenyl]methyl]-3-oxo- (CA INDEX NAME)




L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 302836-17-5 CAPLUS

CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-(3-methoxyphenoxy)phenyl]methyl]-3-oxo- (CA INDEX NAME)

RN 302836-18-6 CAPLUS


CN 2H-1,4-Benzothiazine-6-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-3-oxo- (CA INDEX NAME)

RN 302836-19-7 CAPLUS

CN 2H-1,4-Benzothiazine-7-carboxylic acid,
2-[(4-chlorophenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)

RN 302836-20-0 CAPLUS

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CN 2H-1,4-Benzothiazine-7-carboxylic acid,
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[4-phenoxyphenyl]methyl]-, ethyl ester (CA INDEX NAME)REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE